恩替卡韦治疗慢性乙型肝炎的不良反应及疗效分析  

Analysis of adverse reactions and efficacy of entecavir against chronic hepatitis B

作　　者：李晨[1] 黄朝丰[1] 刘青[1] 曾邦伟[1] 

机构地区：[1]福建医科大学附属协和医院,福建福州350001

出　　处：《中国医院药学杂志》2015年第8期722-725,共4页Chinese Journal of Hospital Pharmacy

基　　金：福建省卫生厅青年科研基金项目(编号:2012-2-41)

摘　　要：目的:研究恩替卡韦治疗慢性乙型肝炎的疗效和不良反应,为临床医生合理选择抗病毒药物提供参考。方法:从某院2010年6月-2013年5月收治的慢性乙型肝炎患者筛选140例HBeAg阳性患者,随机分为恩替卡韦组和拉米夫定联合阿德福韦酯治疗的联合组。用药后,分别在第12周,第24周,第48周及第96周检测HBVDNA的阴转率、HBeAg阴转率、ALT复常率及组织学改善情况等相关疗效指标,全程密切注意患者的不良反应,并对研究数据进行统计学分析。结果:恩替卡韦能有效的抑制HBVDNA的复制,48周HBVDNA阴转率达81.4%,组织学改善率达74.2%,常见不良反应6例,且无需治疗,数日后消失。结论:恩替卡韦治疗慢性乙型肝炎疗效确切,不良反应少,能够改善肝脏功能,值得临床推广应用。OBJECTIVE To study efficacy and adverse reactions of entecavir in the treatment of chronic hepatitis B （CHB）, and provide reference for clinical physicians to choose antiviral drugs. METHODS A total of 140 patients with CHB who were HbeAg positive were randomly divided into entecavir group and group of lamivudine combined with adefovir ester from June 2010 to May 2010 in our hospital. After drug dosing, relevant efficacy parameters, including HBVDNA＇s negative rate, HbeAg negative rate, ALT normalization rate and histologic improvement, were detected respectively in the 12th, 24th , 48th and 96th weeks. Adverse reactions in patients were closely monitored, and research data were statistically analyzed. RESULTS Ente- cavir could effectively inhibit replication of HBVDNA. The 48th week HBVDNA＇s negative rate was 81.4%, and the histologic period was 74. 2%. The common adverse reactions occurred in 6 patients, and disappeared in a few days without no therapy ap- plied. CONCLUSION Enteeavir is effective to patients with CHB, and can improve hepatic function significantly and safely.

关 键 词：恩替卡韦 慢性乙型肝炎 疗效 不良反应 

分 类 号：R969[医药卫生—药理学]